The R&D team of Amy Gene Enterprise and top hospitals at home and abroad have completed dozens of clinical trials based on the core technology of intestinal microorganisms, and accumulated a lot of R&D achievements, including diabetes, obesity, inflammatory skin diseases, stress enteritis, lung cancer and other diseases. The research results are published in Nature Medicine, Nature Biotechnology, Cell System and Cell Host &; Top international magazines such as Microbiology, Intestine, Nature Newsletter and Journal of Dermatological Investigation.
Up to now, Aimi Gene has a series of core technologies, from intestinal microbial gene detection, big data analysis, clinical trial design and implementation, to new strain screening and commercial application. The products of several R&D pipelines are about to start formal clinical application. The enterprise has established Industry-University-Research cooperation with dozens of top hospitals on technologies and products related to intestinal microorganisms, including Shanghai Ruijin Hospital, Shanghai Huashan Hospital, Xi 'an Xijing Hospital, Xi 'an Tang Dou Hospital, Shanghai Institute of Life Sciences of China Academy of Sciences, Nanjing Dermatitis Institute of China Academy of Medical Sciences, Nanjing General Hospital of Nanjing Military Region, Nanjing Gulou Hospital, Shenzhen General Hospital and Shenzhen Children's Hospital.
The brand of Amy gene
Yin Wei
Because micro, Amy Gene's micro-ecological health management brand not only contains two core elements: gene and microorganism, but also has the personalized meaning of "individual". Committed to providing users with accurate, personalized and periodic micro-ecological health solutions based on the genetic detection data of intestinal microorganisms with probiotics as the carrier.
At present, three series of products have been launched, because of micro-brand, because of micro-human genetic testing, because of micro-intestinal microbial testing, because of micro-series probiotics? . A closed-loop service model of congenital+acquired double genome detection and detection+intervention has been formed to provide accurate and comprehensive personalized services for different users.
polymerize
Shenzhen Polymerization Medical Laboratory is set up in the national incubator in Baoan District, Shenzhen, with an area of about 3,000 square meters, including the third-party clinical laboratory (P2 level), gene sequencing laboratory, microbial basic technology development laboratory, new strain preservation and protection laboratory, and new drug research and development laboratory.
Polymerization medical laboratory adheres to the needs of hospitals and patients as the center, and provides accurate and efficient medical laboratory services based on scientific and objective principles. Actively aggregate all kinds of advanced inspection technology, information technology and intelligent technology to continuously improve service quality. Intelligently aggregate all kinds of human biochemical data, genome data and microbial data, and constantly improve the user data system; Effectively aggregate enterprise resources, hospital resources and social resources, and constantly promote the rapid development of the industry.